Notice of Availability of Administrative Supplements for Studies of Cancer in HIV/AIDS

Notice Number: NOT-CA-06-023

Key Dates
Release Date: April 10, 2006

Issued by
National Cancer Institute (NCI), (http://www.cancer.gov/)

Purpose

The Office of AIDS Malignancy Program, Division of Cancer Treatment and Diagnosis, NCI, has set apart funds in fiscal year 2006 (FY06) that are specifically designated for studies of AIDS and HIV-associated cancers. The NCI is requesting applications for administrative supplements for NCI-funded or co-funded R01, R21, P01, U01, P50, P30, and D43 grants. Depending on the merit of the requests received and the availability of funds, the NCI may award up to $1,000,000 in supplemental funding in connection with this funding opportunity announcement in FY06.

All applications requesting these administrative supplements must include information outlining that the applications meet the following conditions: (1) the focus of the awarded grant is related to the focus of the AIDS Cancer research supplement that is being proposed, i.e., the supplement is specifically designated for studies of AIDS and HIV-associated cancers as defined in more detail below; (2) there are no funds in the parent award to specifically pay for the proposed effort; (3) the parent grant is active during the entire funding period of the requested supplement; and (4) the Principal Investigator (PI) for the supplement must be the PI of the parent grant.

These supplements have been designed to provide 1-year funding to peer reviewed, funded investigators who wish to conduct research related to HIV/AIDS and cancer including, but not limited to, basic biology, pathogenic mechanisms, epidemiology, diagnosis, prevention, assessment of risk factors, screening, determination of cancer rates and mortality in the HIV-positive population, treatment of cancers in the HIV-positive population in the era of highly active antiretroviral therapy (HAART), and/or tracking of outcomes of cancer treatment in the HIV-positive population. Examples of research objectives for the supplements may include: (1) development of evaluation tools for identifying barriers to improving accrual of patients for cancer trials conducted in HIV-positive populations; (2) determination of genomic and epigenomic profiles of AIDS-associated cancers; (3) development of improvements in strategies for the prevention of cancer in HIV-positive populations; (4) development of enhancements in the collection of cancer outcome data and sample sets from HIV-related observational cohort studies; (5) elucidation of viral and cellular interactions in the development of cancers frequently observed in the HIV-positive population; (6) discovery and development of novel drug and therapeutic approaches targeting AIDS-associated malignancies; and (7) development of tools and/or training venues for enhancing international collaborations, particularly in countries severely affected by the HIV epidemic.

Detailed instructions for applying for these administrative supplements will be posted at http://ctep.cancer.gov/ on April 15, 2006. The receipt date for administrative supplement applications at the NCI address given below is May 30, 2006.

No specific forms or format is required, although appropriate pages from the PHS 398 form are recommended. The application request should not exceed 10 single-spaced pages including references and should contain sufficient detail (similar to a standard research application) to allow assessment of the scientific merit of the proposed research plans and the appropriateness of the request for supplemental funding (see the web site cited above for more detailed application information). Budgets should not exceed $100,000 in total costs for a time period not exceeding 12 months. All requests require an itemized budget and must be countersigned by the grantee institution's business office. Requests for supplements under this program must comply with NIH policies for inclusion of women, minorities, and children in research involving human subjects. A biosketch of the PI and each collaborating investigator should be included (each biosketch not to exceed 4 pages).

Requests will be evaluated by NCI and NIH program staff (and appropriate consultants) who have expertise in the research area. Awards will be determined on the basis of scientific merit, program relevance, potential to build effective collaborations between basic and clinical investigators, and availability of funds. Biological specimens for AIDS-associated cancer studies are available from the ACSR at no charge (see http://acsb.ucsf.edu/).

Inquiries related to this Notice should be addressed to the NCI Program Director for the particular R01, R21, P01, P30, P50, U01, or D43 for which the supplement is being requested. Before submitting a request letter, each applicant (i.e., PI) is encouraged to discuss the feasibility of their research proposal with the Program Director for the NCI research project parent grant.

The earliest anticipated award date for this program will be September 1, 2006.

Inquiries

Direct inquiries concerning the programmatic and review matters should be directed to:

Kishor Bhatia, Ph.D., MRCPath
Director
Office of AIDS Malignancy Program
6116 Executive Boulevard, Suite 505, MSC 8318
Bethesda, MD 20892-8318 (for U.S. Postal Service express or regular mail)
Rockville, MD 20852 (for express/courier delivery)
Telephone: (301) 496-4995
Fax: (301) 480-4137
bhatiak@mail.nih.gov

Geraldina Dominguez, Ph.D.
Program Director
Office of AIDS Malignancy Program
6116 Executive Boulevard, Suite 505, MSC 8318
Bethesda, MD 20892-8318 (for U.S. Postal Service express or regular mail)
Rockville, MD 20852 (for express/courier delivery)
Telephone: (301) 496-4995
Fax: (301) 480-4137
E-mail: domingug@mail.nih.gov

Direct inquiries regarding administrative and fiscal matters should be directed to:

Eileen Natoli
Office of Grants Administration
National Cancer Institute
6120 Executive Boulevard, EPS Room 243, MSC 7150
Bethesda, MD 20892-7150 (for U.S. Postal Service express or regular mail)
Rockville, MD 20852 (for courier/express delivery)
Telephone: 301-496-8791
E-mail: en10d@nih.gov

Submission of Request

Submit a signed, type written original of the request and an electronic PDF file of the package to

Denise Jenkins
Program Specialist
Office of AIDS Malignancy Program
6116 Executive Boulevard, Suite 505, MSC 8318
Bethesda, MD 20892-8318 (for U.S. Postal Service express or regular mail)
Rockville, MD 20852 (for express/courier delivery)
Telephone: (301) 451-4692
Fax: (301) 480-4137
E-mail: jenkinde@mail.nih.gov

Do Not Submit the Applications to the Center for Scientific Review (CSR).